Mirum Pharmaceuticals
MIRM
327 hedge funds and large institutions have $8.37B invested in Mirum Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 62 funds opening new positions, 127 increasing their positions, 100 reducing their positions, and 43 closing their positions.
101% more call options, than puts
Call options by funds: $12.4M | Put options by funds: $6.18M
44% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 43
33% more capital invested
Capital invested by funds: $6.29B → $8.37B (+$2.07B)
27% more repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 100
25% more funds holding in top 10
Funds holding in top 10: 16 → 20 (+4)
5% more funds holding
Funds holding: 311 → 327 (+16)
4.07% more ownership
Funds ownership: 113.1% → 117.18% (+4.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$171M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$108M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
+$107M |
| 4 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$94.9M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$94.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$106M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$57.7M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$53.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$34.8M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$32.7M |
MIRM Hedge Fund Activity: Q2 2026 in Review
327 of the 8,295 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q2 2026, worth a combined $8.37B — up 33% from $6.29B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new MIRM positions and 43 closed out — a net gain of 19 holders — while 127 added to existing stakes and 100 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $171M. The largest seller was Citadel Advisors, exiting entirely with an estimated $106M sold.
- 327 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q2 2026, up from 311 in Q1 2026.
- Funds reported $8.37B of Mirum Pharmaceuticals stock for Q2 2026, up 33% quarter-over-quarter.
- 62 funds opened new Mirum Pharmaceuticals positions in Q2 2026 and 43 closed out, a net change of +19 holders.
- The largest Mirum Pharmaceuticals buyer in Q2 2026 was Fidelity Investments, an estimated $171M added.
- The largest Mirum Pharmaceuticals seller in Q2 2026 was Citadel Advisors, an estimated $106M sold.
Based on aggregated 13F filings for Q2 2026.